Trials / Completed
CompletedNCT00997945
10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies
A Phase I, Open-label, Single-arm Study to Determine the Single and Multiple Dose Pharmacokinetics of 10mg ZD4054 (Zibotentan) Administered Once Daily in Male, Elderly Chinese Patients With Advanced Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the pharmacokinetics of single and multiple doses of 10mg ZD4054 (Zibotentan) in male, elderly Chinese patients with advanced solid malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZD4054 (Zibotentan) | 10 mg ZD4054 (Zibotentan) once daily on Day1, Day4 to Day15 |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2010-09-01
- Completion
- 2011-04-01
- First posted
- 2009-10-20
- Last updated
- 2011-05-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00997945. Inclusion in this directory is not an endorsement.